Low-level laser therapy (red-light caps, combs and helmets)

Key takeaways

• There is a real but modest signal. The FDA cleared the first device, the HairMax LaserComb, in 2007 as a class II device (FDA 510(k) record). Its four sham-controlled trials (269 people randomized) found terminal hair gains of 18 to 26 per cm2 against 2 to 9 with sham at 26 weeks (Jimenez 2014).
• Pooled data agree. Meta-analyses found more hair density than sham: effect size 1.02 across 15 studies and 795 people (Gupta 2021), 1.32 across 11 double-blind trials (Liu 2019), and 1.14 to 1.44 across 38 studies and 3,098 patients (Perez 2025).
• People do not always notice. In the Cochrane review for women, laser combs raised hair counts but participants did not rate themselves as more improved than with sham (van Zuuren 2016).
• Industry money is everywhere. The HairMax and iGrow trials were funded or supplied by the device makers (Lanzafame 2014).
• Adding it to minoxidil is unproven. Two 2025 meta-analyses disagree: 4 trials showed no added benefit (Alosaimi 2025) and 7 trials showed +6.6 hairs per cm2 (Mawu 2025). A blinded half-head trial in men found no difference between sides (Ferrara 2021).
• Dose matters more than the number of diodes. Hair gain tracked energy per session and total exposure time, and pulsed light did better than continuous (Gupta 2020).
• It is very safe. The pivotal trials reported no serious adverse events, only occasional itch, tenderness, warmth or temporary shedding (Jimenez 2014).
• It is expensive up front. Reported list prices in 2022 ran from about $399 for a comb to about $1,899 for a cap with 272 diodes.

What it is

Low-level laser therapy, also called photobiomodulation, shines red light of about 630 to 680 nm onto the scalp from lasers or LEDs built into combs, caps or helmets. In the US these are FDA-cleared devices, meaning they were judged substantially equivalent to an earlier device. That is a lower bar than the efficacy approval that drugs such as minoxidil and finasteride went through (FDA product code OAP). Marketing status in the EU and UK was not checked.

How it works

Red light is absorbed by photoreceptors in skin cells. The leading idea is that follicle stem cells are stimulated and follicles move into the growth phase. This is plausible and supported by lab and animal work, but the human mechanism is not directly proven.

What the studies show

• Leavitt 2009, 110 men, 26 weeks: a laser comb raised terminal hair density against a sham device (P under 0.0001). The study was run by the device company (Leavitt 2009).
• Kim 2013, 40 people, 24 weeks: an LED helmet raised density and diameter against sham, though patients' own global rating did not differ (Kim 2013).
• Lanzafame 2013, 44 men, 16 weeks: 35 to 39% more hair than placebo, in a trial funded by the maker (Lanzafame 2013).
• Lanzafame 2014, 47 women, 16 weeks: +100 vs +24 hairs in a 2.85 cm2 area (Lanzafame 2014).
• Esmat 2017, 45 women, 4 months: an LED helmet performed about like 5% minoxidil, and the combination did best. There was no sham group (Esmat 2017).
• Ferrara 2021, 21 men: no added benefit from light over 5% minoxidil in a half-head trial (Ferrara 2021).
• Thomas 2025, 160 people randomized, 26 weeks: no single arm reached the main goal, though pooled arms gained 28.5 hairs per cm2 more than sham. Many participants were excluded from the per-protocol analysis (Thomas 2025).
• Guidelines: the Japanese guideline recommends LED and low-level laser for male pattern loss (Manabe 2018), and a 2025 Canadian consensus put it in the near-consensus recommended tier (Landells 2025). A 2025 consensus found red-light photobiomodulation does not cause DNA damage, though some panellists had industry ties (Maghfour 2025).

How to read this: sham-controlled device trials are short, mostly sponsor-run and measure small areas of scalp. Sham devices glow like the real ones, but red-light devices also feel warm, so patients may guess which they have. Pooled studies show very high heterogeneity, so the true size of the gain is uncertain. A 2024 network meta-analysis in men ranked oral 5-alpha-reductase inhibitors above photobiomodulation.

How it's used in studies

• Wavelength: about 650 to 655 nm red laser or LED, sometimes 630 to 660 nm diodes.
• Schedule: sessions of 8 to 25 minutes, 3 times a week or every other day. Some LED helmets were used daily for 10 to 18 minutes.
• Judging results: trials assessed hair at 16 to 26 weeks. Most stopped at 6 months, so what happens after stopping is unknown.
• Less frequent schedules did at least as well as more frequent ones (Liu 2019).
• Most trials enrolled Norwood IIa to V or Ludwig I to II and skin types I to IV. Fully bald areas without living follicles will not respond, and evidence for very dark skin and advanced baldness is thin.

Side effects and safety

No serious adverse events were reported in the pivotal trials. Reported nuisances are temporary shedding, itch, scalp tenderness, warmth and dryness. Do not look into the beams. How well light reaches the scalp through very dense or coily hair has not been studied.

Bottom line

Light devices are a low-risk optional extra on top of proven treatment, not a replacement for minoxidil or finasteride. They suit people who want a no-side-effect add-on and can afford the upfront cost. Check the specific device's FDA clearance, wavelength and that its protocol matches published trials, and judge it after 4 to 6 months. See the treatment ladder. Discuss with a doctor.